UNSPSC 51142411: Rizatriptan

This classification denotes a serotonin agonist with the molecular formula C15H19N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 51086HBW8G, chemically known as 1h-indole-3-ethanamine, n,n-dimethyl-5-(1h-1,2,4-triazol-1-ylmethyl)- but generally known as rizatriptan, which bears US NIH Compound Identifier 5078. European Medicines Agency schedules Rizatriptan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10346MIG.

UNSPSC 51142411 Rizatriptan, a Commodity code, does not align with recent state and local procurement activity posted under this classification. The three recent opportunities recovered show Rizatriptan coded but substantially concern naloxone procurement, direct-to-manufacturer pharmacy initiatives, and multi-source generic pharmaceuticals distribution through cooperative purchasing — none of which involve migraine-specific triptans. The code shows little relevant recent activity; the mismatch suggests either miscoding by issuing bodies or an artifact of database tagging that does not reflect actual buying patterns under this Commodity designation.

The issuing bodies capturing these opportunities span state health departments and county health agencies: Seminole County, Florida (health procurement), the Texas Health and Human Services Commission (pharmacy benefit program strategy), and the Minnesota Department of Administration through the multistate MMCAP cooperative vehicle (generic pharmaceuticals and OTC distribution across state and local members including Oregon). Geographic activity appears concentrated in Florida, Texas, and the upper Midwest cooperative membership. Representative recent solicitations include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2026) for naloxone and drug deactivation systems on a two-year contract with renewal option; Texas HHS's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription fulfillment; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating jurisdictions, with awarded vendors effective July 1, 2026. Neither opportunity specifically targets Rizatriptan or migraine therapeutics. Firms pursuing this code should verify actual buying intent with issuing bodies or monitor for future solicitations that correctly reflect triptan procurement.